ABSTRACT
BACKGROUND Meta-analyses have found anti-TNF drugs to be the best treatment, on average, for Crohn’s disease. We performed a subgroup analysis to determine if it is possible to achieve more efficacious outcomes by individualizing treatment selection.
METHODS We obtained participant-level data from 15 trials of FDA-approved treatments (N=5703). We used sequential regression and simulation to model week six disease activity as a function of drug class, demographics, and disease-related features. We performed hypothesis testing to define subgroups based on rank-ordered preferences for treatments. We queried health records from University of California Health (UCH) to estimate the impacts these models could have on practice. We computed the sample size needed to prospectively test a prediction of our models.
RESULTS 45% of the participants (N=2561) showed greater efficacy with at least one drug class (anti-TNF, anti-IL-12/23, anti-integrin) over another. They were classifiable into 6 subgroups, two showing greatest efficacy with anti-TNFs (36%, N=2064). Women over 50 showed superior responses with anti-IL-12/23s. Although they represented only 2% of the trial-based cohort, 25% of Crohn’s patients at UCH are women over 50 (N=5,647), consistent with potential selection bias in trials. Moreover, 75% of biologic-exposed women over 50 did not receive an anti-IL12/23 first-line, supporting the potential value of these models. A future trial with 250 patients per arm will have 97% power to confirm the superiority of anti-IL-12/23s over anti-TNFs in these patients. A treatment recommendation tool is available at https://crohnsrx.org.
CONCLUSIONS Personalizing treatment can improve outcomes in Crohn’s disease. Future work is needed to confirm these findings, and improve representativeness in Crohn’s trials.
BACKGROUND AND CONTEXT Patients with Crohn’s disease likely harbor different underlying susceptibilities to different treatments. Yet, clinical practice today is guided by cohort-averaging studies that ignore patient-level variation. Personalized treatment strategies are needed.
NEW FINDINGS We re-analyzed data from 15 trials to model individual outcomes to different treatments. We found 6 subgroups, including women over 50 whose superior responses to anti-IL-12/23s deviate from the majority trend.
LIMITATIONS This was a meta-analysis of trial data; confirmatory prospective studies are needed. Our models need to be updated to include recently approved treatments.
CLINICAL RESEACH RELEVANCE Our findings confirm that heterogeneity of treatment effect does exist in Crohn’s disease. A future trial with 250 patients per arm is 97% powered to show that anti-IL-12/23s are more efficacious than anti-TNFs in women over 50. Incidentally, we also found evidence of possible selection bias into Crohn’s trials. Future work is needed to study and rectify this.
BASIC RESEARCH RELEVANCE We found that patients do in fact harbor different underlying susceptibilities to different treatment mechanisms of action. But the biological basis of this is unknown. Future studies designed to elucidate this may reveal new therapeutic targets in Crohn’s disease.
Competing Interest Statement
VAR received grant support from Janssen, Alnylam, Merck, Genentech, and Blueprint Medicines for unrelated work during this study. DVA is currently an employee at Bristol Myers Squibb. AJB is a co-founder and consultant to Personalis and NuMedii; consultant to Mango Tree Corporation, and in the recent past, Samsung, 10x Genomics, Helix, Pathway Genomics, and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, and Merck, and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Meta (Facebook), Alphabet (Google), Microsoft, Amazon, Snap, 10x Genomics, Illumina, Regeneron, Sanofi, Pfizer, Royalty Pharma, Moderna, Sutro, Doximity, BioNtech, Invitae, Pacific Biosciences, Editas Medicine, Nuna Health, Assay Depot, and Vet24seven, and several other non-health related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Johnson and Johnson, Roche, Genentech, Pfizer, Merck, Lilly, Takeda, Varian, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Westat, and many academic institutions, medical or disease specific foundations and associations, and health systems. Atul Butte receives royalty payments through Stanford University, for several patents and other disclosures licensed to NuMedii and Personalis. Atul Butte's research has been funded by NIH, Peraton (as the prime on an NIH contract), Genentech, Johnson and Johnson, FDA, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governor's Office of Planning and Research, California Institute for Regenerative Medicine, L'Oreal, and Progenity. The authors have declared that no actual competing interests exist.
Clinical Protocols
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=157827
Funding Statement
This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 TR001872. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. VAR was partially supported by an institutional training grant (5T32DK007007-48) funded by the NIH and administered by UCSF. Additional funding support for data access was provided by the University of San Francisco.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the UCSF Institutional Review Board (#18-24588)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The raw data are owned by the sponsors of the trials that were meta-analyzed in this work. This data may be accessed for reproduction and extension of this work following an application on the YODA and Vivli platforms and execution of a data use agreement. The analytical code is available at https://github.com/rwelab/CrohnsRx.
